News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Launch of 20 new medicines expected by 2030
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Subscribe To Our Newsletter & Stay Updated
